| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
915 |
855 |
$96K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
815 |
809 |
$92K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
470 |
459 |
$46K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
478 |
456 |
$45K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
390 |
367 |
$28K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
390 |
367 |
$10K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
797 |
712 |
$2K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
108 |
91 |
$2K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
261 |
241 |
$883.26 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
280 |
136 |
$711.02 |
| 81025 |
|
109 |
99 |
$352.76 |
| 81003 |
|
179 |
161 |
$72.18 |
| H0033 |
Oral medication administration, direct observation |
95 |
83 |
$10.00 |